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Abstract
Background: The applications of proteomic strategies to ovine medicine remain limited. The definition of serum
proteome may be a good tool to identify useful protein biomarkers for recognising sub-clinical conditions and
overt disease in sheep. Findings from bovine species are often directly translated for use in ovine medicine. In order
to characterize normal protein patterns and improve knowledge of molecular species-specific characteristics, we
generated a two-dimensional reference map of sheep serum. The possible application of this approach was tested
by analysing serum protein patterns in ewes with mild broncho-pulmonary disease, which is very common in
sheep and in the peripartum period which is a stressful time, with a high incidence of infectious and parasitic
diseases.
Results: This study generated the first reference 2-DE maps of sheep serum. Overall, 250 protein spots were
analyzed, and 138 identified.
Compared with healthy sheep, serum protein profiles of animals with rhino-tracheo-bronchitis showed a significant
decrease in protein spots identified as transthyretin, apolipoprotein A1 and a significant increase in spots identified
as haptoglobin, endopin 1b and alpha1B glycoprotein.
In the peripartum period, haptoglobin, alpha-1-acid glycoprotein, apolipoprotein A1 levels rose, while transthyretin
content dropped.
Conclusions: This study describes applications of proteomics in putative biomarker discovery for early diagnosis as
well as for monitoring the physiological and metabolic situations critical for ovine welfare.
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Background
The application of proteomic approaches over the last
decade has provided new tools for clarifying the molecu-
lar aspects of physiological states, and for understanding
the etiology and pathogenesis of many diseases. Never-
theless, proteomic studies in veterinary medicine, par-
ticularly in the ovine species, remain limited compared
with human medicine. Proteomics performs large-scale
protein analysis, describes the entire protein comple-
ment of a cell, tissue, biological fluid or organism and
provides information on protein expression, localization,
functions and interactions. This approach could help in
recognising sub-clinical conditions that compromise the
product quality of an entire flock. For farm animals such
as cows, sheep, and goats, the description of metabolic
imbalances could serve to improve nutritional breeding
management. If imbalances are not corrected they can
lead to serious consequences in the food chain and fi-
nancial losses.
Proteomics has been applied in studies on cows [1-4],
horses [5], swine [6], chickens [7], and some domestic
pets [8], to define the protein profiles of tissues and
body fluids during stressful conditions, pathological
states, and infections.
In the last decade proteomic technologies were success-
fully used in the discovery phase of biomarker identifica-
tion [9], identifying many proteins that discriminated the
“healthy” state from the “disease” states. This step has to
be followed up by other phases that validate markers and
prove and establish efficacy [10]. Knowledge of species-
specific protein peculiarity is crucial in ovine medicine, as
findings from bovine species are often directly translated
for use in sheep. Characterization of serum and plasma
proteomes has helped define new diagnostic and
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prognostic markers for humans and for a few other spe-
cies [1-4,6,11-13].
The goals of this study were to define the serum sheep
proteome and identify protein markers that recognize
early and subclinical disease. A two-dimensional electro-
phoresis gel reference map of the sheep serum protein
profile was generated as the first essential step. In
addition, two applications of proteomic approaches in
ovine medicine were tested. Serum protein changes were
analysed in sheep during the peripartum period, and in
animals with mild respiratory diseases.
Peripartum is a crucial period in the reproductive cycle
of a lactating ruminant [14,15]. The metabolic and im-
munological status, feeding, and environmental condi-
tions change rapidly and intensively [16]. In ewes,
metabolic disorders and the risk of infections increase
[17,18]. Inadequate management can affect the product-
ivity and profitability of an animal or entire flock
[14,15,18-21].
Respiratory diseases are commonly found in sheep
flocks and can cause significant financial losses. In small
ruminants, these diseases are often due to a combination
of different causes such as viral and bacterial infections,
physiological stress, poor management and environmental
factors and also adverse weather conditions [22,23]. Diag-
nosis is often too late and based on post-mortem findings
that need to be confirmed by serological markers.
We analysed serum from sheep with rhino-tracheo-
bronchitis or in peripartum status to identify candidate
markers that could be used to indicate the need for imme-
diate attention, thus improving clinical management of
flocks. Challenges in ovine medicine include the definition
of risk factors on farms, the design control strategies and
the enhancement of productivity and livestock welfare.
Responding will improve animal health and reduce finan-
cial loss.
The high abundance proteome of sheep serum was
identified and its usefulness in the biomarker discovery
was described, suggesting novel scenarios in investiga-
tion of both physiological and pathological conditions.
Results
2-DE sheep serum maps
This study generated the first reference 2-DE gel maps
of sheep serum using pH 3–10 (Figure 1) and pH 4–7
(Figure 2) IPG strips, and 9–16 T% SDS-PAGE. The pH
3–10 IPG showed more than 250 spots, most of which
were identified as predominant, highly abundant pro-
teins like albumin, and immunoglobulins and their iso-
forms and fragments. Some had a horizontal train aspect
which is typical of glycosylated/phosphorylated proteins.
Common serum proteins that have been detected in
other species such as humans, horses, chickens, and cat-
tle were observed. Sheep serum protein profiles were
improved using pH 4–7 IPG strips. Maps in this pH
range had more than 350 spots. Most serum proteins
had a pI in the acid range, as can be seen in Figure 2
and most acid proteins showed better resolution in gels
covering pH 4–7.
Our preliminary study was designed to detect less
abundant serum proteins. We used common strategies
for protein depletion in sheep serum like Aurum™Affi-
Gel Blue kit (Bio-Rad), the ProteoPrep immunoaffinity al-
bumin and IgG depletion kit (SIGMA), Albumin & IgG
Depletion SpinTrap™ (GE Healthcare). Unfortunately,
abundant proteins were not significantly depleted, while
less abundant proteins were reduced or sometimes elimi-
nated (data not shown) [24]. This was unsuccessful prob-
ably because the kits used were designed for human
samples. As the methodology was not suitable for our
aims in this study it was abandoned and we focussed on
non pre-fractionated samples.
MS analysis was performed to identify protein spots
from the reference 2-DE gel, and determine protein spots
that changed in diseased sheep or during the peripartum
period. Protein spots were excised, in-gel digested with
trypsin, and peptides were analyzed by MS. Overall, 250
protein spots were analyzed, and 138 were identified, cor-
responding to 42 proteins. Details of MS protein spot
identification are shown in Table 1. In one protein spot
(52), two proteins were present. Many proteins were
identified in more than one spot. In particular, serum al-
bumin was identified in 40 spots. The diverse protein
species were probably due to post-translational modifica-
tions, truncations or degradation of mature proteins.
Many of the non-identified spots led to very good MS
and MS/MS data, but returned no hits from the data-
bases. This might be due to the incomplete sheep gen-
ome sequencing. Some high quality MS data could not
be assigned to sheep proteins, but matched bovine pro-
teins; one MS data set matched a horse protein. The
identification of proteins in other organisms is because
proteins are highly conserved between sheep and cows.
Thus, protein spots contain corresponding orthologs in
sheep serum.
Differentially expressed proteins
We tested the usefulness of 2-DE maps of sheep serum,
and the efficiency of the proteomic approach in demon-
strating variations in serum protein patterns during early
stage disease or particular physiological states. As
described in the Methods section, we studied serum pro-
tein changes in sheep with RTB.
Serum protein profiles from healthy sheep and sheep
affected by RTB are compared in Figure 3A. Overall, 17
protein spots exhibited a fold change (fc) (calculated as a
ratio of average density spots in RTB vs average density
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spots in healthy controls) that was more than 2 or less
than 0.5 with statistically significant P< 0.05 (Figure 3B).
In diseased animals we observed a reduction in the
two spots corresponding to apolipoprotein A-1 (area 1).
A significant decrease was observed for a spot identified
as transthyretin (area 2). In contrast, the intensity of
three spots identified as haptoglobin was on average
five-fold higher (area 3). Significant increases were
detected in four spots corresponding to endopin 1b (area
4) and in six spots identified as alpha1B glycoprotein
(area 5).
We also compared the serum profiles of pregnant
healthy sheep two months before the expected delivery
date (basal), at lambing, and 15 days after delivery
(+ 15 days) (Figure 4A). Fold change was calculated as a
ratio of average density spots at lambing and +15 days
vs basal (Figure 4B). As above, spots with fc more than 2
or less than 0.5 with statistically significant P< 0.05 were
accepted.
Modifications of acute phase proteins were observed.
The intensities of three spots identified as haptoglobin
were significantly higher at lambing than two months
before delivery (area 1). A similar trend was found for
alpha-1-acid glycoprotein, which increased at lambing
but returned to basal levels within two weeks (area 2). A
transthyretin spot intensity before parturition (basal),
was higher than at lambing and two weeks after delivery
(area 4). Surprisingly, we found that three apolipoprotein
A1 spots increased at lambing and after 15 days (area 3).
Discussion
This paper reports the first proteomic application of 2-
DE combined with MS analysis to characterise the total
protein profile of sheep serum. Our 2-DE gels can be
considered the first reference maps of sheep serum.
Most of the serum proteins that are usually used as ani-
mal clinical biomarkers were identified. Even though
specific new biomarkers are needed for the management
Figure 1 2-DE reference map of sheep serum pH 3–10. Representative 2-DE map of sheep serum obtained by performing the first dimension
(IEF) on IPG strips pH 3–10 and the second dimension on 9 –16 % gradient SDS-PAGE gels. The protein spots were visualized by Coomassie blue
staining. The indicated spots were excised from gel and identified by MALDI-TOF MS and MS/MS. The results of MS identification are reported in
Table 1. Mr standard values are indicated on the left.
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of the main diseases that affect sheep, this farm species
has been investigated less than others, such as cattle [1-4].
In some cases, therapeutic protocols and diagnostic range
values for sheep are borrowed from closely related species
such as other ruminants. 2-DE gel reference maps of
human, rat, bovine, swine, chicken and horse have been
defined [1-7,11,12] highlighting species-specific differences
in serum protein profiles.
In the present study, many of the proteins we identi-
fied are found in different species, with different pI and
molecular weights, and different isoforms and pheno-
types [6]. Considering the central role that serum plays
in clinical diagnostics, the characterization of 2-DE gel
serum sheep protein profiles increases the tools available
for ovine medicine, both for identification of new disease
markers, and for improved understanding of the physio-
logical and pathological functions of proteins in diseased
and healthy sheep.
SELDI-TOF MS has recently been applied to analyse
ovine serum [25]. It might be considered complemen-
tary to 2-D electrophoresis, because it is able to detect
proteins and peptides with a very low molecular mass
(< 10–20 kDa). However, many of the proteins with a
high molecular weight that could be useful as serum
tissue markers remain unrevealed. On the contrary, 2D-
electrophoresis cannot detect proteins with a low molecu-
lar mass or pI values <4 or >9.
The map presented here is an integral serum 2-DE
map which was obtained from whole serum protein con-
tent. Serum is rich in proteins such as albumin and im-
munoglobulin, that can mask less abundant proteins.
Nonetheless, we decided to avoid sample pre-treatments,
such as dealbumination, that could change the protein
composition of our specimens. Our first goal was to pro-
vide a map for use in clinical diagnostic and prognostic
purposes without pre-fractionating as it might have
Figure 2 2-DE reference map of sheep serum pH 4–7. Representative 2-DE map of sheep serum obtained by performing the first dimension
(IEF) on IPG strips pH 4–7 and the second dimension on 9 –16 % gradient SDS-PAGE gels. The protein spots were visualized by Coomassie blue
staining. The indicated spots were excised from gel and identified by MALDI-TOF MS and MS/MS. The results of MS identification are reported in
Table 1. Mr standard values are indicated on the left.
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1 α 1 Antitripsin A1AT_SHEEP 45.984/5.83 63.0/4.47 17 2 279 m
2 α 1 Antitripsin A1AT_SHEEP 45.984/5.83 62.8/4.55 14 10 311 e
3 α 1 Antitripsin A1AT_SHEEP 45.984/5.83 63.7/4.40 16 9 249 e
4 α 1 Antitripsin A1AT_SHEEP 45.984/5.83 50.5/4.43 7 2 45 m
5 α 1 Antitripsin A1AT_SHEEP 45.984/5.83 50.4/4.52 9 3 99 m
6 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 74.1/4.39 16 5 176 m Bovine
7 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 73.3/4.48 9 4 146 m Bovine
8 α 1 acid Glycoprotein A1AG_BOVIN 23.182/5.62 46.1/3.35 6 2 82 m Bovine
9 Amine Oxidase AOCX_BOVIN 84.756/5.57 90.1/5.10 19 5 161 m Bovine
10 Apolipoprotein A1 O02762_SHEEP 66.173/4.61 25.2/5.24 18 8 256 m
11 Apolipoprotein A1 O02762_SHEEP 66.173/4.61 25.7/5.01 11 3 137 m
12 Apolipoprotein A1 O02762_SHEEP 66.173/4.61 26.0/4.80 31 16 650 m
13 Apolipoprotein A1 O02762_SHEEP 66.173/4.61 26.2/4.63 13 2 235 m
14 Apolipoprotein A1 O02762_SHEEP 66.173/4.61 26.0/5.51 15 8 273 e
15 Ceruloplasmin CERU_SHEEP 119.126/5.50 137.2/5.06 16 5 267 m
16 Ceruloplasmin CERU_SHEEP 119.126/5.50 137.8/5.15 15 7 279 m
17 Ceruloplasmin CERU_SHEEP 119.126/5.50 137.1/5.01 14 6 218 m
18 Protein kinase KAPCA_SHEEP 40.589/8.71 32.5/3.66 11 3 95 m
19 Complement component 3 O97941_BOVIN 17.044/5.25 67/9.38 5 2 81 m Bovine
20 Corticotropin releasing factor CRFR1_SHEEP 47.558/9.63 93.7/5.46 7 2 62 m
21 Fetuin Precursor FETUA_SHEEP 38.680/5.17 69.7/4.02 7 4 157 m
22 Fetuin Precursor FETUA_SHEEP 38.680/5.17 56.2/4.04 8 3 116 m
23 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 75.6/4.16 14 6 218 m Bovine
24 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 74.8/4.23 12 6 239 m Bovine
25 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 74.5/4.26 21 13 366 m Bovine
26 α 1B Glycoprotein A1BG_BOVIN 53.553/5.30 73.9/4.35 11 2 88 m Bovine
27 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 56.0/6.31 6 2 81 m Bovine
28 Fibrinogen β chain FIBB_BOVIN 53.339/8.45 56.6/6.00 14 7 175 e Bovine
29 Fibrinogen β chain FIBB_BOVIN 53.339/8.45 55.0/6.54 16 6 200 m Bovine
30 Fibrinogen β chain FIBB_BOVIN 53.339/8.45 55.0/6.70 11 4 132 m Bovine
31 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 74.4/6.96 5 2 90 m Bovine
32 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 74.7/6.86 4 2 78 m Bovine
33 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 74.0/6.72 11 3 73 m Bovine
34 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 74.4/6.78 5 2 61 m Bovine
35 Fibrinogen α chain FIBA_BOVIN 67.012/6.73 65.3/6.94 9 2 87 m Bovine
36 Fibrinogen β chain FIBB_BOVIN 53.339/8.45 65.3/6.81 17 4 130 m Bovine
37 Gelsolin F2YQ13_SHEEP 80.719/5.59 94.4/5.87 13 4 156 m
38 Haptoglobin HPT_BOVIN 44.859/7.83 36.7/6.38 9 4 185 m Bovine
39 Haptoglobin HPT_BOVIN 44.859/7.83 36.6/6.56 18 5 222 m Bovine
40 Haptoglobin HPT_BOVIN 44.859/7.83 36.6/6.53 17 4 182 m Bovine
41 Haptoglobin HPT_BOVIN 44.859/7.83 36.6/6.66 7 2 76 m Bovine
42 Hemoglobin β HBB_SHEEP 16.073/6.75 12.7/7.82 23 8 516 m
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Table 1 List of identified sheep serum proteins (Continued)
43 Hemoglobin β HBB_SHEEP 16.073/6.75 12.6/8.24 21 7 428 m
44 α globin chain Q28745_SHEEP 15.178/7.94 12.2/8.70 17 11 306 m
45 α globin chain Q28745_SHEEP 15.178/7.94 12.2/9.72 18 10 491 m
46 Ig λ -1 chain CAA494511 51.564/5.65 41.0/8.69 4 3 141 e
47 Ig λ -1 chain CAA494511 51.564/5.65 41.0/8.82 7 5 158 e
48 Ig λ -1 chain CAA494511 51.564/5.65 41.0/8.97 7 3 137 e
49 Ig λ -1 chain CAA494511 51.564/5.65 51.4/8.65 8 6 150 e
50 Ig mu chain AAA513791 53.545/5.10 80.9/5.31 17 12 319 m
51 Ig mu chain AAA513791 53.545/5.10 80.9/5.45 16 12 314 m
52 Apolipoprotein A1 AAI02942 30.276/5.71 26.9/5.68 24 7 399 m Bovine
IgG α λ-chain AAU45093 11.328/8.48 26.9/5.68 19 10 337 m
53 IgG α λ-chain AAU45093 11.328/8.48 26.6/9.11 14 6 202 m
54 IgG α λ-chain AAU45093 11.328/8.48 26.7/8.27 9 3 113 m
55 IgG α λ-chain AAU45093 11.328/8.48 27.6/6.39 14 5 286 m
56 IgG α λ-chain AAU45093 11.328/8.48 26.4/9.43 11 4 146 m
57 IgG α λ-chain AAU45093 11.328/8.48 51.2/8.78 7 2 98 m
58 Ig λ -1 chain CAA494511 51.564/5.65 51.1/8.69 5 2 68 m
59 IgG α λ-chain AAU45093 11.328/8.48 26.1/9.95 13 2 118 m
60 IgG α λ-chain AAU45093 11.328/8.48 27.1/5.13 7 3 115 m
61 Ig mu chain AAA513791 53.545/5.10 52.4/6.85 8 2 102 m
62 α Tripsin Inhibitor Chain H4 ITIH4_BOVIN 101.512/6.22 119.4/5.52 7 2 82 m Bovine
63 Muscle Endopin 1b SPA33_BOVIN 46.326/6.05 126.3/4.18 6 2 88 m Bovine
64 Muscle Endopin 1b SPA33_BOVIN 46.326/6.05 126.4/4.28 16 4 142 m Bovine
65 Retynol-Binding protein RET3_SHEEP 27.992/3.49 22.2/5.59 14 6 287 m
66 Serum albumin ALBU_SHEEP 69.188/5.80 44.3/5.22 13 8 236 m
67 Serum albumin ALBU_SHEEP 69.188/5.80 42.0/5.23 12 6 193 e
68 Serum albumin ALBU_SHEEP 69.188/5.80 39.8/5.53 19 10 359 m
69 Serum albumin ALBU_SHEEP 69.188/5.80 34.7/5.52 17 7 279 m
70 Serum albumin ALBU_SHEEP 69.188/5.80 46.6/5.23 9 4 138 m
71 Serum albumin ALBU_SHEEP 69.188/5.80 34.8/5.95 14 8 258 m
72 Serum albumin ALBU_SHEEP 69.188/5.80 35.6/5.77 15 6 212 m
73 Serum albumin ALBU_SHEEP 69.188/5.80 16.5/4.68 12 5 167 e
74 Serum albumin ALBU_SHEEP 69.188/5.80 16.1/5.05 16 7 222 m
75 Serum albumin ALBU_SHEEP 69.188/5.80 21.8/4.53 15 9 326 m
76 Serum albumin ALBU_SHEEP 69.188/5.80 22.1/4.47 15 10 332 m
77 Serum albumin ALBU_SHEEP 69.188/5.80 23.9/4.41 16 9 335 m
78 Serum albumin ALBU_SHEEP 69.188/5.80 11.2/4.36 11 5 176 e
79 Serum albumin ALBU_SHEEP 69.188/5.80 11.3/4.06 8 2 93 e
80 Serum albumin ALBU_SHEEP 69.188/5.80 9.6/3.93 7 4 119 m
81 Serum albumin ALBU_SHEEP 69.188/5.80 116.4/5.69 7 2 71 m
82 Serum albumin ALBU_SHEEP 69.188/5.80 116.3/5.74 10 2 115 e
83 Serum albumin ALBU_SHEEP 69.188/5.80 93.5/5.53 21 11 353 m
84 Serum albumin ALBU_SHEEP 69.188/5.80 92.8/6.08 19 8 275 m
85 Serum albumin ALBU_SHEEP 69.188/5.80 31.3/6.29 18 6 248 m
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Table 1 List of identified sheep serum proteins (Continued)
86 Serum albumin ALBU_SHEEP 69.188/5.80 31.3/6.55 13 5 173 m
87 Serum albumin ALBU_SHEEP 69.188/5.80 30.8/6.83 14 7 273 m
88 Serum albumin ALBU_SHEEP 69.188/5.80 27.4/6.70 15 6 237 m
89 Serum albumin ALBU_SHEEP 69.188/5.80 25.5/6.94 16 6 254 m
90 Serum albumin ALBU_SHEEP 69.188/5.80 26.4/7.03 15 8 270 m
91 Serum albumin ALBU_SHEEP 69.188/5.80 26.4/7.25 14 5 195 m
92 Serum albumin ALBU_SHEEP 69.188/5.80 25.7/7.16 16 5 219 m
93 Serum albumin ALBU_SHEEP 69.188/5.80 36.5/6.26 13 7 265 m
94 Serum albumin ALBU_SHEEP 69.188/5.80 74.3/3.05 15 7 261 m
95 Serum albumin ALBU_SHEEP 69.188/5.80 27.2/5.40 5 2 75 m
96 Serum albumin ALBU_SHEEP 69.188/5.80 24.7/6.24 8 4 161 m
97 Serum albumin ALBU_SHEEP 69.188/5.80 25.5/6.38 5 2 88 e
98 Serum albumin ALBU_SHEEP 69.188/5.80 24.6/6.69 17 10 369 m
99 Serum albumin ALBU_SHEEP 69.188/5.80 93.5/5.68 14 7 222 m
100 Serum albumin ALBU_SHEEP 69.188/5.80 43.0/4.76 6 2 87 m
101 Serum albumin ALBU_SHEEP 69.188/5.80 49.3/6.46 23 13 456 e
102 Serum albumin ALBU_SHEEP 69.188/5.80 49.4/6.30 21 12 401 m
103 Serum albumin ALBU_SHEEP 69.188/5.80 63.704 15 8 276 m
104 Serum albumin ALBU_SHEEP 69.188/5.80 63.9/6.08 22 13 461 m
105 Serum albumin ALBU_SHEEP 69.188/5.80 150.2/5.64 21 10 362 m
106 Transferrin O18780_SHEEP 66.454/8.29 77.5/6.44 12 4 125 m
107 Transferrin O18780_SHEEP 66.454/8.29 77.3/6.33 13 4 145 m
108 Transferrin O18780_SHEEP 66.454/8.29 76.9/6.54 8 3 142 e
109 Transferrin O18780_SHEEP 66.454/8.29 82.1/6.66 18 8 279 m
110 Transferrin O18780_SHEEP 66.454/8.29 82.8/6.22 6 2 60 m
111 Transferrin O18780_SHEEP 66.454/8.29 82.1/6.32 6 3 117 m
112 Transthyretin TTHY_SHEEP 15.770/5.59 13.0/5.87 15 9 375 e
113 Transthyretin TTHY_SHEEP 15.770/5.59 13.1/5.42 18 14 479 e
114 Apolipoprotein AII APOA2_BOVIN 11.201/7.80 10.0/4.03 5 2 77 m Bovine
115 VitD Binding Protein VTDB_BOVIN 53.342/5.36 64.7/4.48 5 2 104 m Bovine
116 VitD Binding Protein VTDB_BOVIN 53.342/5.36 64.7/4.56 5 2 46 m Bovine
117 VitD Binding Protein VTDB_BOVIN 53.342/5.36 63.2/4.86 4 2 40 m Bovine
118 VitD Binding Protein VTDB_BOVIN 53.342/5.36 62.9/4.92 5 2 59 e Bovine
119 Zn A2 Glycoprotein ZA2G_BOVIN 33.851/5.11 50.2/3.66 13 7 271 m Bovine
120 Factor XIIa Inhibitor F12AI_BOVIN 51.723/6.19 88.4/4.06 6 2 82 e Bovine
121 Factor XIIa Inhibitor F12AI_BOVIN 51.723/6.19 88.1/4.12 6 3 119 m Bovine
122 Factor XIIa Inhibitor F12AI_BOVIN 51.723/6.19 87.8/4.18 9 3 148 m Bovine
123 Ig mu chain AAA513791 53.545/5.10 82.8/4.88 13 3 120 m
124 Ig mu chain AAA513791 53.545/5.10 81.8/5.01 14 5 152 m
125 Ig λ -6a light chain AAB94911 11.718/4.65 24.2/4.87 11 4 135 m
126 Ig G heavy chain AAB37381 35.848/6.09 53.8/6.31 7 2 68 m Bovine
127 Paraoxonase 1 Q2KIW1_BOVIN 39.841/5.24 46.8/3.89 9 4 137 m Bovine
128 Paraoxonase 1 Q2KIW1_BOVIN 39.841/5.24 46.6/4.01 8 3 122 e Bovine
129 Muscle Endopin 1b SPA33_BOVIN 46.326/6.05 126.6/4.38 10 6 192 m Bovine
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Table 1 List of identified sheep serum proteins (Continued)
130 Muscle Endopin 1b SPA33_BOVIN 46.326/6.05 126.4/4.58 11 7 204 m Bovine
131 Fetuin FETUA_SHEEP 38.680/5.17 68.1/4.06 8 2 83 m
132 Fetuin FETUA_SHEEP 38.680/5.17 67.7/4.12 10 4 172 m
133 Fetuin FETUA_SHEEP 38.680/5.17 66.2/4.01 12 7 209 m
134 Fetuin FETUA_SHEEP 38.680/5.17 56.2/4.42 11 5 163 m
135 Gelsolin F2YQ13_SHEEP 80.719/5.59 94.4/5.87 10 6 214 e
136 Gelsolin F2YQ13_SHEEP 80.719/5.59 92.8/6.08 13 8 245 e
137 Corticotropin 550074A 45.421/6.51 93.6/5.30 17 11 316 m
138 Corticotropin 550074A 45.421/6.51 93.9/5.38 10 4 141 m
a) Number refer to protein spots indicated in Figures.
b) Accession number from SWISS-PROT or NCBI entry is given.
c) MOWSE score required for significant homology (P< 0.05); "m" indicates MALDI-TOF/TOF-MS; "e" indicates CE-ESI-MS.
d) Sheep protein or homologue to.
e) Values for Mr and pI experimentally determined for each spot according to marker proteins.
Figure 3 Differential 2-DE analysis of serum in sheep with RTB. A) 2-DE serum sheep map and expanded view of the gel portions including
the deregulated proteins. Spot proteins differing by> 2 fold (P< 0.05) in sheep with RTB compared to healthy sheep (control) were indicated.
Area 1: spots identified as Apo A-1; Area 2: spots identified as TTR; Area 3: spots identified as Hp; Area 4: spots identified as EP; Area 5: spots
identified as α1BGP. B) Histograms representing log fold change (calculated as a ratio of average density spots in RTB vs average density spots in
healthy controls). *: Spots with fold change more than 2 or less than 0.5 with statistically significant P< 0.05.
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changed protein quantity or quality. Major serum pro-
teins might be modified in physiological conditions or
disease, and consequently, all sample treatments that
could mask these changes should be avoided.
Since minor protein components might be involved in
metabolism and regulation, one future challenge might be
the definition of good depletion strategies or pre-fractioning
methods for sheep serum to enhance the identification
of low-abundance proteins without altering sample cha-
racteristics as has recently been applied to other animal
species [26].
The usefulness of the serum reference 2-DE map was
confirmed by two different comparative investigations. The
first ascertained serum protein pattern differences between
healthy sheep and sheep affected by RTB, a common sheep
disease. The second one, using a different group of animals,
determined the serum protein changes during the peripar-
tum period of four weeks before, and two-three weeks after
lambing. The goal was to demonstrate the possible applica-
tion of this proteomic approach in a mild pathological situ-
ation and in the physiological stressful peripartum
condition, because in both situations it is important to rec-
ognise early signs of sub-clinical conditions.
Similar to previous studies on bovine and swine species
[4,6], we observed variations in proteins associated with
the acute phase in both cases. Both in RTB affected and in
lambing sheep, we saw a decrease in TTR a globular non-
glycosylated protein, which is considered to be both a
thyroxin- and a holo-retinol-binding protein. TTR is
synthesized by different tissues such as the liver, retina,
pancreas and placental trophoblast [27]. It performs a
multiplicity of biological functions [28]. In particular, it
plays a major and critical role in transport of maternal
thyroid hormone to the developing fetus [27]. TTR in-
volvement in various central nervous system disorders,
diabetes melitus, preclampsia has been described [29-31].
Figure 4 Differential 2-DE analysis of sheep serum during peripartum. A) 2-DE serum sheep map and expanded view of the gel portions
including the deregulated proteins during peripartum. Spot proteins differing by> 2 fold (P< 0.05) in sheep at lambing (lambing), 15 days after
lambing (+15 days) compared to sheep two months before lambing (basal) were indicated. Area 1: spots identified as Hp; Area 2: spots identified
as α1AGP; Area 3: spots identified as Apo A-1; Area 4: a spot identified as TTR. B) Histograms representing log fold change (calculated as a ratio of
average density spots at lambing and +15 days vs basal). *: Spots with fold change more than 2 or less than 0.5 with statistically significant
P< 0.05. Black and grey bars correspond to lambing vs basal and +15 vs basal respectively.
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Reduced TTR serum concentrations are often associated
with acute phase response, which may be due to inflam-
mation, trauma or other disorders like malnutrition
[32,33]. A decrease in TTR during inflammation has been
reported as an effect of proinflammatory cytokines such
as IL-1 and IL-6 [34]. These findings also explain the de-
crease in Apo A-1 that we observed in serum from sheep
affected by RTB. Apo A-1 is the major protein fraction of
high-density lipoproteins, and is considered a negative
acute-phase protein [35,36]. During acute inflammation,
IL-6, IL-1β, and TNF-α upregulate the expression of the
pentraxins (C-reactive protein and serum amyloid-P),
which in turn inhibit the synthesis of Apo A-1 [37].
In contrast, we observed a significant increase in Apo
A-1 after lambing, which can be explained by the effect
of oestrogens. In females, these hormones enhance Apo
A-1 levels. In sheep and other ruminants, delivery is
induced by an increase in biosynthesis of oestrogens
related to progesterone, and an enhancement of the
oestrogen/progesterone ratio [38]. A similar situation
occurs in humans, but not in other animal species such
as horses, and this again confirms the necessity to de-
termine species differences. The above considerations
also confirm that some proteins of the acute phase have
other functions more important in specific situations.
The hormonal changes that occur during lambing and
influence lipid transport for lactation are the probable
causes of the observed increase in Apo A-1. In sheep
affected by RTB, Apo A-1 behaves as a negative acute-
phase protein. In these animals, the decrease in nega-
tive acute phase proteins TTR and Apo A-1, was
related to the increase in Hp [39], a serum protein with
several functions. Its main role is to bind free haemo-
globin to allow hepatic recycling of haeme iron, and to
prevent iron loss and renal damage. As a haemoglobin
scavenger, this protein reduces circulating iron and
inhibits enzymatic and non-enzymatic reactions cata-
lysed by iron [40]. Hp also acts as an antioxidant, has
antibacterial activity, and is involved in modulating
aspects of the acute phase response [41]. Its blood level
is associated with the prevalence and clinical evolution
of many inflammatory diseases including infections, de-
generative disorders and autoimmune disorders. Hp is
considered a major positive acute-phase protein [42],
and its increase was more evident in diseased sheep
than in lambing sheep.
The appropriate response to lambing, a critical situ-
ation with rapid, intense homeostatic changes, depends
on good welfare conditions and an adequate nutritional
status. Thus, management of this period is crucial for
the health of the ewe, and to prevent disease or infec-
tions like mastitis [43,44]. Increased α1AGP after lamb-
ing confirmed the stress response during delivery. This
acute phase protein has been reported to be involved in
similar stressful conditions, inflammation or tissue de-
struction [45-47].
Although variations in Hp, α1AGP and TTR confirm
lambing induces an acute phase reaction, the increase in
Apo A-1 indicates a metabolic modification may also be
taking place. These proteins may be suggested as puta-
tive bio-markers to monitor the adaptive response and
metabolic changes in peripartum.
However, in both disease and lambing conditions, no
changes were found in other acute phase proteins such
as alpha1-antitrypsin. In serum from sheep affected by
RTB, we also found an increase in EP. This protein
belongs to a large family of serine proteinase (elastase,
trypsin, plasmin, chymotrypsin) inhibitors that are essen-
tial regulators of a wide variety of biological processes
[48]. In particular, EP can strongly inhibit elastase. This
protease plays a crucial role in tissue destruction and
inflammation in numerous diseases, including chronic
obstructive pulmonary disease, cystic fibrosis, adult re-
spiratory distress syndrome, and ischemic-reperfusion
injury. EP may play a major role in inflammation and
during response to infections in which elastase is par-
ticularly involved. In bovine serum, EP content is high,
suggesting its involvement in the acute phase response,
with other protease inhibitors [49]. The increase in RTB
sheep serum of α1BGP, a plasma protein related to the
immunoglobulin supergene family, is not clear because
its biological role is currently unknown. However, it
might be involved in the reaction to infection, and it is
considered an acute phase protein. It increases in Myco-
bacterium bovis infected cows [50], but decreases in pigs
with viral infections [6]. Even if EP and α1BGP are
minor acute phase proteins, their trends suggest further
studies are needed to clarify their roles in respiratory/
infections disease in sheep and to assess their potential
use as putative biomarkers.
Conclusions
Proteomics has helped discover biomarkers for a large
number of human diseases. It has rarely been used in
sheep but could serve as a tool to identify protein bio-
markers that might be useful for recognising subclinical
and pathological conditions, certifying welfare and the
quality/safety of ovine products. In the present study a
proteomic approach based on 2-DE combined with MS
revealed the ovine serum protein pattern and identified
42 medium-high-abundance proteins that could poten-
tially serve as biomarkers in early diagnoses and moni-
toring of ovine physiology and metabolism. Most were
acute phase proteins, even though they act as carry and
transport proteins in blood, bind hormones, cytokines
and other physiologically important compounds, or are
released by dead or damaged cells. Consequently, this
study provides the first requisite for proteomic
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application in ovine medicine and the basis for future
investigations that will be designed to specifically assess
protein variations in physiological and pathological con-
ditions. Potential applications of our proteomic approach
were established by protein variations found in ewes
with mild disease and in peripartum period. The road
towards a proteomics-based diagnostic test in sheep is
still long. This step has to be followed by other phases
and markers, sensitivity and specificity need to be tested
and established after appropriate validation before efficacy
can be assessed using different diagnostic methodologies.
Methods
Animals
Two-to-three-year-old nulliparus Comisana ewes were
used. All animals were kept at the Didactic and Research
estate of the Faculty of Veterinary Medicine, Perugia
University, and received the same diet.
Ten healthy sheep were used to generate the reference
2-DE gel maps and as a control group (control).
Seven sheep with signs and symptoms of mild rhino-
tracheo-bronchitis were diagnosed by clinical findings
and objective examination. They showed increased re-
spiratory rate, coughing, thick nasal discharge, and
dyspnoea.
Seven pregnant healthy sheep two months before the
expected delivery date (basal), at lambing (lambing), and
15 days (+15 days) after parturition were used to study
protein changes during peripartum.
The control and pregnant healthy sheep were selected
based on the results of individual physical examination,
which included body condition score, clinical evaluation
of cardio-pulmonary function, feeding history, a close
examination of nose, mouth, eyes, neck and skin, and
palpation of the udders to determine if they were healthy
and functional [51].
Serum was obtained from blood samples, collected
from sheep by veterinary staff, which had already been
used to develop routine clinical or health management
practices in the flock, following the guidelines of Animal
Care and Use Committee of the University of Perugia.
Moreover, this study was carried out in accordance with
the EU directive 2010/63/EU for animal experiments.
Serum samples, obtained after centrifugation, were
mixed with inhibitor protease cocktail (SIGMA) and
stored at −80°C.
2-D electrophoresis and image analysis
Serum samples containing 800 μg of total proteins
(about 10–15 μL) were treated with equal volume of
2.3% DTE, 2% CHAPS at 95°C for 5 min, and diluted in
IEF sample buffer (final volume 350 μL) containing 8 M
urea, 2 M thiourea, 2% CHAPS, 30 mM Tris, 100 mM
DTT, 0.8% ampholytes (Bio-Rad) and bromophenol blue
traces. IPG strips (17 cm, pH 3–10 or 4–7) (Bio-Rad)
were rehydrated for 12 h at 50 V. Protein concentration
was estimated by using the Bradford assay (Bio-Rad)
according to the manufacturer 's instructions. Proteins
were focused using a Protean IEF Cell (Bio-Rad) at 20°C,
with low initial voltage followed by a voltage gradient
from 10000 Vh to 95000 Vh, with a limiting current of
50 μA/strip. After focusing, proteins were reduced by in-
cubating the IPG strips with 5 mM tributylphosphine in
10 mL of equilibration buffer (375 mM Tris–HCl pH
8.8, 6 M urea, 20%w/v glycerol, 2%w/v SDS) for 14 min,
and alkylated with 2.5%w/v iodoacetamide in 10 mL of
equilibration buffer for 14 min. Electrophoresis in the
second dimension was carried out in gradient slab poly-
acrylamide gels (9–16%T) (180 x 240 x 1 mm) in a Pro-
tean XL Multi-cells apparatus (Bio-Rad), hosting six gels
simultaneously. IPG strips were laid on top of the gels
with 0.5% agarose in the cathode buffer (192 mM gly-
cine,15 mM Tris, 0.1% SDS, pH 8.3) containing bromo-
phenol blue. The anode buffer consisted of 375 mM
Tris–HCl pH 8.8. Gels were run at 10°C for the first
hour at 5 mA/gel and at 10 mA/gel overnight until the
dye front reached the bottom of the gel. 2-DE gels were
stained with colloidal Coomassie blue G250 (0.12% Blue
G-250 (SIGMA), 20% v/v methanol, 10% v/v o-phos-
phoric acid, 10%w/v ammonium sulphate (SIGMA) and
destained in 5% acetic acid [52]. Each sample was ana-
lyzed in triplicate.
For image analysis, stained 2-DE gels were immedi-
ately scanned using a Bio-Rad GS-800 calibrated densi-
tometer. (Images were analyzed with PDQuest (V7.2)
2-DE gel analysis software (Bio-Rad). Protein spots were
detected using the PDQuest software instructions. A
reference gel image was created that included all spot in-
formation in a matchset, with all the gel images matched
using “classic matching” with defined landmarks. All gels
compared were matched in one matchset, and the refer-
ence gel used to assign spot numbers across all the gels,
so that the same spot on each individual gel was
assigned to the corresponding spot number for compari-
son. Isoelectric points and molecular weight were esti-
mated by parallel electrophoresis with a mixture of pI
and Mr protein standards (Bio-Rad).
Qualitative and quantitative analysis of protein pat-
terns were conducted by using PDQuest. Master gels
were created from four replicated gels from each sheep
at each experimental stage. Spots were detected,
matched and normalised using the parameter “total of
all valid spots”. The threshold for accepting a meaningful
variation was a two-fold change, and statistical analysis
for significant differences was performed exporting data
from PDQuest software to software R by ANOVA. Ana-
lysis of variance was followed by the Bonferroni-type
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multiple comparison to evaluate statistical differences
between basal, lambing, and +15 days. (P <0.05 was
considered significant).
MS analysis
Coomassie-stained protein spots were excised and
destained with 50% ACN in 50 mM ammonium bicar-
bonate and dried by addition of ACN and incubation in
a speedvac evaporator. Dried gel pieces were rehydrated
in 40 mM ammonium bicarbonate and 10% ACN con-
taining 12 ng/μL trypsin (Promega), and incubated for
60 min on ice. The trypsin solution was removed and
replaced with 40 mM ammonium bicarbonate and 10 %
ACN. After digestion overnight at 37°C, all liquid was
collected and the remaining gel pieces extracted twice
using 50 μL 5% TFA containing 10% ACN for 30 min
with constant shaking. All fluids were combined, dried
in a speedvac evaporator and dissolved in 10 μL 10%
ACN, 0.2% TFA. About one μL of this peptide solution
was applied to a MALDI target (Daltonics) and mixed
with two μg CHCA dissolved in 50% ACN, 0.2% TFA as
matrix using the dried droplet technique. After
crystallization, mass spectra were recorded with an Ultra-
flex TOF/TOF I mass spectrometer (Bruker Daltonik)
operating with FlexControl 2.4, FlexAnalysis 2.4, Bio-
Tools 3.0 and WARP-LC 1.1 software. Some protein
spots were identified using capillary electrophoresis (CE,
P/ACE MDQ-System, Beckman Coulter) coupled to a
3D ion trap mass spectrometer (IT-MS, Esquire3000+,
Bruker Daltonik). Briefly, extracted peptides were sepa-
rated in a 90-cm capillary tube with an inner diameter of
75 μm, containing 0.5 M formic acid and 10% ACN as
CE buffer. A stacking method was applied, with 30 nL of
1.5 M NH3 loaded into the capillary tube followed by
210 nL of sample, 30 nL 1.0 M formic acid and 20 nL CE
buffer. Separation occured in 30 min at 30 kV. The capil-
lary outlet was mounted directly to the electrospray ion
source of the IT-MS, and stabilized by addition of 50%
isopropanol as sheath liquid (3 μL/min). The ion trap
was operated in AutoMSn using a top-2 method and
CID mode. Scan range was from 50 to 2200 m/z in MS
and MS/MS mode. All obtained spectra were combined
and analyzed. To identify proteins, Swissprot and MSDB
and NCBI database searches using Mascot 2.0 software
were performed considering variable modifications like
oxidation of methionine, carbamidomethylation of cyst-
eine, deamidation, and acetylation at the N-terminus.
One missed cleavage was allowed and mass tolerance
was set to <100 ppm for precursor ions and 0,6 Da for
fragment ions. Peptides were considered identified if the
peptide ion score was above 25, and proteins were identi-
fied by at least two unique peptides. If no sheep protein
was identified but an orthologous protein was assigned
to the MS and MS/MS spectra this protein was taken as
identified and the name and accession No of the ortholo-
gous protein was given. Additionally, this protein was
checked using a BLAST search.
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